HCWB - HCW Biologics Inc

HCWB - HCW Biologics Inc

https://www.hcwbiologics.com

Recent News

Powered by Alpha Vantage

Why Is HCW Biologics Stock Surging 102% Overnight? - HCW Biologics ( NASDAQ:HCWB )

Benzinga • 3 days, 12 hours ago • score: 0.22

HCW Biologics Inc. HCWB shares skyrocketed 102.72% to $6.73 in after-hours trading on Thursday following the company's announcement of the successful development of second-generation T-cell engagers targeting solid tumors. Check out the current price of HCWB stock here.

HCW Biologics Shares Soar On Breakthrough Second-Generation Cancer Immunotherapy - HCW Biologics ( NASDAQ:HCWB )

Benzinga • 2 weeks, 6 days ago • score: 0.06

HCW Biologics' new pembrolizumab-based fusion therapy showed stronger immune activation and tumor infiltration than standard treatments. The company will present details of its second-generation checkpoint inhibitor at Nova Southeastern University on Sept. 12.

HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform - HCW Biologics ( NASDAQ:HCWB )

Benzinga • 3 weeks ago • score: 0.09

HCWB stock up 58.79% at $5.48 with volume at 10.85M vs 132.51K average. TRBC fusion drug outperforms Keytruda in pancreatic cancer preclinical studies. See the 6X seasonal strategy set to target this fall's biggest opportunities. Details here → HCW Biologics Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$62.40

52W Low

$2.77

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.70

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-3.63

EV/Revenue (<3 favorable)

16.18

P/S (TTM) (<3 favorable)

10.95

P/B (<3 favorable)

2.80

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

27.30%

Institutions (25–75% balanced)

1.00%

Shares Outstanding

2,151,600

Float

1,135,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

832,840

Gross Profit (TTM)

166,570

EPS (TTM)

-16.41

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-528.87%

ROE (TTM) (>15% strong)

-277.26%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.99

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—